News | April 27, 2022
Syngene full-year revenue from operations up 19% to Rs. 2604 crore
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
Subscribe To Our Newsletter & Stay Updated
